#123425
Re: Farmas USA
KPTI
Actividad potente en el combinado
https://www.onclive.com/view/selinexor-triplet-shows-strong-clinical-activity-in-relapsed-refractory-myeloma
Los datos intermedios que se preveían para agosto han salido pero solo seguridad, no eficacia, que anuncian para septiembre/octubre.
Creo que nos vamos hacia los 15.
"Commenting on the progress to date, a Karyopharm representative noted that the company is “encouraged about the progress of the trial.” An interim safety analysis including the first 40 patients did not identify any safety issues. The study is expected to be completed in August, and the company reported that it may be able to report some initial efficacy results by September or October."
De aquí:
Actividad potente en el combinado
https://www.onclive.com/view/selinexor-triplet-shows-strong-clinical-activity-in-relapsed-refractory-myeloma
Los datos intermedios que se preveían para agosto han salido pero solo seguridad, no eficacia, que anuncian para septiembre/octubre.
Creo que nos vamos hacia los 15.
"Commenting on the progress to date, a Karyopharm representative noted that the company is “encouraged about the progress of the trial.” An interim safety analysis including the first 40 patients did not identify any safety issues. The study is expected to be completed in August, and the company reported that it may be able to report some initial efficacy results by September or October."
De aquí:
BTK Inhibitors, Other Blood Cancer Drugs Are Being Tapped for COVID-19
«Después de nada, o después de todo/ supe que todo no era más que nada.»
